# Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)

> **NCT00783211** · PHASE4 · COMPLETED · sponsor: **Organon and Co** · enrollment: 722 (actual)

## Conditions studied

- Seasonal Allergic Rhinitis

## Interventions

- **DRUG:** desloratadine
- **DRUG:** fexofenadine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00783211
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08-01
- **Primary completion:** 2004-10-01
- **Final completion:** 2004-10-01
- **Target enrollment:** 722 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783211, "Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00783211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*